Circulating metabolites serve as diagnostic biomarkers for HER2-positive breast cancer and have predictive value for trastuzumab therapy outcomes.
J Clin Lab Anal
; 36(2): e24212, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-34994982
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Biomarkers, Tumor
/
Trastuzumab
/
Antineoplastic Agents, Immunological
Type of study:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
J Clin Lab Anal
Journal subject:
TECNICAS E PROCEDIMENTOS DE LABORATORIO
Year:
2022
Type:
Article
Affiliation country:
China